Dialysis fluid endotoxin level and mortality in maintenance hemodialysis: a nationwide cohort study.

BACKGROUND The quality of dialysis fluid water might play an important role in hemodialysis patient outcomes. Although targeted endotoxin levels of dialysis fluid vary among countries, evidence of the contribution of these levels to mortality in hemodialysis patients is lacking. STUDY DESIGN Retrospective cohort study using data from the Japan Renal Data Registry, a nationwide annual survey. SETTING & PARTICIPANTS 130,781 patients receiving thrice-weekly in-center hemodialysis for more than 6 months were enrolled at 2,746 facilities in Japan at the end of 2006. None of the patients changed facility or treatment modality during 2007. PREDICTOR Highest endotoxin level in dialysis fluid reported by each facility during 2006. Patients were categorized by facility endotoxin level into the following groups: <0.001, 0.001 to <0.01, 0.01 to <0.05, 0.05 to <0.1, and ≥0.1EU/mL. Age, sex, dialysis vintage, diabetes mellitus as a primary cause of end-stage renal disease, Kt/V, normalized protein catabolic rate, dialysis session duration, serum albumin, and hemoglobin were measured as potential confounders. OUTCOME All-cause mortality, censored by transplantation; withdrawal from dialysis treatment; or end of follow-up. RESULTS Of 130,781 hemodialysis patients, 91.2% had facility endotoxin levels below the limit set for dialysis fluid in Japan (<0.05EU/mL). During a 1-year follow-up, 8,978 (6.9%) patients died of all causes. The rate of all-cause mortality at 1 year was highest in the ≥0.1-EU/mL category (88.0 deaths/1,000 person-years). Patients in the ≥0.1-EU/mL group exhibited an increased risk of all-cause mortality of 28% (95% CI, 10%-48%) compared to the <0.001-EU/mL group. LIMITATIONS Endotoxin level in dialysis fluid is reported as categorical data. No information about variation in endotoxin levels in dialysis fluid over time. CONCLUSIONS Higher facility endotoxin levels in dialysis fluid may be related to increased risk for all-cause mortality among hemodialysis patients. Correcting this modifiable facility water management practice might improve the outcome of hemodialysis patients.

[1]  Takayuki Hamano,et al.  Overview of Regular Dialysis Treatment in Japan (as of 31 December 2011) , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[2]  Patrick Royston,et al.  Multiple Imputation by Chained Equations (MICE): Implementation in Stata , 2011 .

[3]  K. Iseki,et al.  Tachycardia as a predictor of poor survival in chronic haemodialysis patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  T. Hasegawa,et al.  An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2007) , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  H. Hirakata,et al.  Standard on Microbiological Management of Fluids for Hemodialysis and Related Therapies by the Japanese Society for Dialysis Therapy 2008 , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  T. Akizawa,et al.  Ultrapure Dialysate Influences Serum Myeloperoxidase Levels and Lipid Metabolism , 2009, Blood Purification.

[7]  K. Iseki,et al.  Bacteriological Qualities of Dialysis Fluid in Japan as of 31 December 2006 , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[8]  K. Wakai,et al.  Overview of Regular Dialysis Treatment in Japan as of 31 December 2006 , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[9]  I. Masakane.  Review: Clinical Usefulness of Ultrapure Dialysate— Recent Evidence and Perspectives , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[10]  K. Fushimi,et al.  An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2001) 1 , 2004, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[11]  R. Wolfe,et al.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Journal of the American Society of Nephrology : JASN.

[12]  R. Fischer,et al.  Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  Naoki Matsuhashi,et al.  Endotoxin-Free Dialysate Improves Response to Erythropoietin in Hemodialysis Patients , 2002, Nephron.

[14]  I. Ichikawa,et al.  Embryogenesis of the congenital anomalies of the kidney and the urinary tract. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  C. Wanner,et al.  Section IV. Dialysis fluid purity. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  R. Fischer,et al.  Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  G. Lonnemann.  Chronic Inflammation in Hemodialysis: The Role of Contaminated Dialysate , 2000, Blood Purification.

[18]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[19]  I Ledebo,et al.  Defining the microbiological quality of dialysis fluid. , 1999, Artificial organs.

[20]  Y. Berland,et al.  Using Ultrapure Water in Hemodialysis Delays Carpal Tunnel Syndrome , 1991, The International journal of artificial organs.

[21]  J. Vienken,et al.  Dialysate contamination and back filtration may limit the use of high-flux dialysis membranes. , 1989, ASAIO transactions.

[22]  L. Henderson,et al.  Hemodialysis Hypotension: The Interleukin Hypothesis , 1983 .